Authors:
Belldegrun, A
Tso, CL
Zisman, A
Naitoh, J
Said, J
Pantuck, AJ
Hinkel, A
de Kernion, J
Figlin, R
Citation: A. Belldegrun et al., Interleukin 2 gene therapy for prostate cancer: Phase I clinical trial andbasic biology, HUM GENE TH, 12(8), 2001, pp. 883-892
Authors:
Freedland, SJ
Sutter, ME
Naitoh, J
Dorey, F
Csathy, GS
Aronson, WJ
Citation: Sj. Freedland et al., Clinical characteristics in black and white men with prostate cancer in anequal access medical center, UROLOGY, 55(3), 2000, pp. 387-390
Authors:
Cangiano, T
Liao, J
Naitoh, J
Dorey, F
Figlin, R
Belldegrun, A
Citation: T. Cangiano et al., Sarcomatoid renal cell carcinoma: Biologic behavior, prognosis, and response to combined surgical resection and immunotherapy, J CL ONCOL, 17(2), 1999, pp. 523-528
Authors:
Seltzer, MA
Barbaric, Z
Belldegrun, A
Naitoh, J
Dorey, F
Phelps, ME
Gambhir, SS
Hoh, CK
Citation: Ma. Seltzer et al., Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer, J UROL, 162(4), 1999, pp. 1322-1328
Authors:
Naitoh, J
Kaplan, A
Dorey, F
Figlin, R
Belldegrun, A
Citation: J. Naitoh et al., Metastatic renal cell carcinoma with concurrent inferior vena caval invasion: Long-term survival after combination therapy with radical nephrectomy, vena caval thrombectomy and postoperative immunotherapy, J UROL, 162(1), 1999, pp. 46-50